Cannabidiol is under clinical development by Zynerba Pharmaceuticals and currently in Phase II for DiGeorge Syndrome. According to GlobalData, Phase II drugs for DiGeorge Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol overview

Cannabidiol (ZYN-002) is under development for the treatment of neuropsychiatric disorders including developmental epileptic encephalopathy in children and adolescents, Fragile X syndrome in children and adolescents, adult refractory focal seizures, pediatric autism spectrum disorder (ASD) (pervasive developmental disorder) and 22q11.2 deletion syndrome. It is applied transdermally as a gel. The drug candidate targets cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and also fatty acid amide hydrolase. It was also under development for the treatment of rheumatoid arthritis and knee pain due to osteoarthritis. It was under development for drug and alcohol addiction.

Zynerba Pharmaceuticals overview

Zynerba Pharmaceuticals, formerly AllTranz, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include refractory epileptic focal, fragile x syndrome, developmental and epileptic encephalopathies and autism spectrum disorder. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.

For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.